Abstract:

Alzheimer's disease (AD) is the most common cause of dementia.Early diagnosis is very important for improving the condition and delaying the progression of AD.However, the current clinical diagnosis requires invasive cerebrospinal fluid detection or expensive amyloid β (Aβ)/Tau-PET examination, which limits the clinical popularization.In recent years, with the application of hypersensitive detection techniques, it has been found that the concentrations of amyloid and phosphorylated Tau in blood correlate well with those in cerebrospinal fluid and the Aβ/Tau-PET scan results.In addition, blood biomarkers of neurodegeneration, such as neurofilament light chains and glial fibrillary acidic protein,can reflect early pathological damage in AD,which can be used to predict disease progression and monitor treatment response.Therefore, this article reviews the research progress of blood biomarkers for AD, in order to improve the understanding of blood biomarkers in the diagnosis and treatment of AD,and provide guidance for their application in the early diagnosis of AD.

Key words: Alzheimer's disease, Blood biomarkers, Ultrasensitive detection technology, Early diagnosis